Lipopharma is a pioneering clinical-stage biopharmaceutical company that focuses its activities on the discovery, design and clinical development of a new generation of medicines that act through the selective regulation of membrane lipids, a novel therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Lipopharma arose as an academic spin-off, founded to turn new scientific breakthroughs and discoveries made by scientists at the Institute of Health Science Research (IUNICS - part of the University of the Balearic Islands in Mallorca, Spain) into a new class of innovative lipid-regulator therapeutic agents that we believe have dramatic game-changing potential in the treatment of life-threatening conditions like cancer, CNS, inflammatory or metabolic diseases
Palma de Mallorca, April 07, 2015. – Lipopharma announced today that a key patent for the company, owned by the University of the Balearic Islands (UIB) and licensed in exclusive to Lipopharma, has been granted by the United States Patent and Trademark Office (USPTO). The patent has been published with number 9000042 and covers potential oncology indications of its lead product Minerval, currently being evaluated in a multicentre Phase I/IIa clinical study in patients with advanced solid tumours, including malignant glioma (MIN-001-1203).
Palma de Mallorca, November 04th, 2014. Lipopharma presented today at BIO-Europe 2014, the leading biotechnological event in Europe, held in Frankfurt (Germany) 3-5 November, the main highlights of its Phase I/IIA clinical trial with Minerval for the treatment of glioma and other solid tumours. The presentation was in the Next Generation track and the main results of the first 5 cohorts in the MIN-001-1203 study have been presented. No safety issues have arisen at doses of up to 8g/day while two objective responses have been reported, one of then in a GBM patient showing a sustained Partial Response after more than 1 year of continued treatment.